Similarly, p53 promoter methylation results in deactivation and causes an increased risk of cancers such as breast carcinomas, gliomas, acute lymphoblastic leukemia, hepatocellular carcinomas, and ovarian cancer [40–44], as well as ESCC in the study area specifically. This evidence concerns the gene TP53 and breast carcinoma.